Myriad Genetics, Inc.
MYGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$374.96M
Close$
$-1.81
141.2% downside
Current Fair Value
141.2% downsideOvervalued by 141.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $374.96 Million |
|---|---|
| Enterprise Value | $462.06 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.96 |
| Beta | 1.64 |
| Outstanding Shares | 93,700,000 |
Return
| Return on Equity | -118.52% |
|---|---|
| Return on Assets | -59.36% |
| Return on Invested Capital | -71.02% |
Valuation & Multiples
| P/E Ratio | -0.93 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.55 |
| Price to Book Ratio | 1.47 |
| Enterprise Value to Revenue | 0.56 |
| Enterprise Value to EBIT | -1.2 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$202.42 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$207.42 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8261▲ 82.61% |
|---|---|
| Total Calls | 20,700▲ 18.97% |
| Total Puts | 17,100▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 228.16%▲ 129.10% |
|---|---|
| Total Invested | $518.39M▼ 8.72% |
| Investors Holding | 203▼ 18.00% |
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...